5 completed, 1 active not recruiting, 1 terminated. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow 10-1074: new trials by email Literature Review of 10-1074 trials Research Report on 10-1074
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 - HIV Infection | Phase 1 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 118 | 2021-05-21 | 2026-08-26 |
| Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants PGT121, PGDM1400, 10-1074 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2019-07-17 | 2022-07-11 |
| Dual bNAb Treatment in Children ART, VRC01LS, 10-1074 - HIV Infection | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2019-06-17 | 2026-05-04 |
| Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions VRC-HIVMAB060-00-AB (VRC01), 10-1074, Normal Saline Placebo - HIV | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2019-04-04 | 2021-10-12 |
| 3BNC117 and 10-1074 in ART-treated Individuals 3BNC117, 10-1074, Analytical treatment interruption - Human Immunodeficiency Virus | Phase 1 | Completed | Rockefeller University | 26 | 2018-06-05 | 2025-10-01 |
| 3BNC117 and 10-1074 in HIV Uninfected Adults 3BNC117, 10-1074, Placebo - Human Immunodeficiency Virus | Phase 1 | Completed | Rockefeller University | 24 | 2016-06-23 | 2018-04-17 |
| 3BNC117 and 10-1074 in HIV-infected Individuals 3BNC117, 10-1074, Analytical treatment interruption - Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | Rockefeller University | 34 | 2016-06-01 | 2018-08-21 |
Acquired Immunodeficiency Syndrome (3) · HIV Infections (3)
National Institute of Allergy and Infectious Diseases (NIAID) (4) · Rockefeller University (3)
United States (6) · Botswana (1) · Germany (1)
Marina Caskey, MD (2) · Daniel Kuritzkes, MD (1) · Magdalena Sobieszczyk (1) · Mathias Lichterfeld, MD, PhD (1) · Michael C Sneller, M.D. (1) · Roger Shapiro, MD, MPH (1) · Sharon Mannheimer (1) · Timothy Wilkin, MD, MPH (1) · Yehuda Cohen, MD (1)
PMID 31393868, PMID 32838558, PMID 36094485, PMID 37406137, PMID 37802566, PMID 38536810, PMID 40136003, PMID 41078080, PMID 41697750